Baseline characteristics of patients with or without proximal LAD stenosis
| Proximal LAD n=559 | Non-proximal LAD n=529 | P value | |
| Mid-LAD lesion | 73.7 (412/559) | 93.4 (494/529) | <0.001 |
| Apical LAD lesion | 14.8 (83/559) | 20.4 (108/529) | 0.017 |
| Age (years) | 66 (58–72) | 65 (58–72) | 0.663 |
| Sex | 1.000 | ||
| Male | 80.1 (448/559) | 80.2 (424/529) | |
| Female | 19.9 (111/559) | 19.8 (105/529) | |
| Body mass index (kg/m2) | 28 (25–30) | 27 (25–31) | 0.769 |
| Diabetes | 27.7 (155/559) | 26.5 (140/529) | 0.682 |
| On insulin | 11.3 (63/559) | 10.8 (57/529) | 0.847 |
| Metabolic syndrome | 48.9 (217/444) | 49.6 (210/423) | 0.839 |
| Hypertension | 66.0 (369/559) | 69.4 (367/529) | 0.244 |
| Dyslipidaemia | 77.4 (429/554) | 78.2 (408/522) | 0.826 |
| Current smoking | 20.2 (113/559) | 19.3 (102/528) | 0.761 |
| Previous MI | 33.6 (186/554) | 40.2 (210/522) | 0.027 |
| Previous cerebrovascular disease | 14.0 (78/556) | 13.5 (71/527) | 0.860 |
| Previous stroke | 4.5 (25/557) | 4.8 (25/526) | 0.885 |
| Previous transient ischemic attack | 4.1 (23/556) | 5.9 (31/526) | 0.209 |
| Previous carotid artery disease | 8.6 (48/559) | 6.6 (35/529) | 0.253 |
| Peripheral vascular disease | 8.9 (50/559) | 9.5 (50/529) | 0.834 |
| COPD | 7.9 (44/559) | 9.3 (49/529) | 0.448 |
| Chronic kidney disease | 19.7 (99/502) | 18.6 (90/483) | 0.686 |
| Creatinine clearance (mL/min) | 80 (63–102) | 82 (65–104) | 0.703 |
| LVEF (%) | 60 (50–67) | 60 (50–65) | 0.909 |
| Congestive heart failure | 5.2 (29/554) | 4.8 (25/522) | 0.781 |
| Clinical presentation | |||
| Silent ischaemia | 13.1 (73/559) | 14.6 (77/529) | 0.483 |
| Stable angina | 61.2 (342/559) | 56.0 (296/529) | 0.085 |
| Unstable angina | 25.8 (144/559) | 29.5 (156/529) | 0.175 |
| EuroSCORE | 4 (2–5) | 3 (2–5) | 0.771 |
| Parsonnet score | 6 (3–12) | 6 (3–12) | 0.825 |
| Disease type | 0.016 | ||
| 2VD (no LMCAD) | 1.9 (10/529) | 4.5 (25/559) | |
| 3VD (no LMCAD) | 98.1 (519/529) | 95.5 (534/559) | |
| Number of lesions | 5 (4–6) | 5 (4–6) | 0.797 |
| SYNTAX score | 30 (24–37) | 24 (18–30) | <0.001 |
| SYNTAX score tercile | |||
| Low | 20.8 (116/559) | 44.6 (236/529) | <0.001 |
| Intermediate | 39.9 (223/559) | 36.3 (192/529) | 0.236 |
| High | 39.4 (220/559) | 19.1 (101/529) | <0.001 |
| Predicted 10-year mortality rates by SYNTAX Score II 2020 (%) | 20.9 (12.1–34.2) | 20.2 (11.3–33.6) | 0.259 |
| Any total occlusion | 28.8 (161/559) | 28.4 (150/529) | 0.893 |
| Any bifurcation | 77.8 (435/559) | 71.3 (377/529) | 0.015 |
| Number of stents | 5 (4–6) | 5 (4–6) | 0.448 |
| Total stent length per patient | 92 (68–120) | 92 (64–124) | 0.723 |
| Off-pump CABG | 14.3 (40/279) | 14.1 (34/241) | 1.000 |
| Number of total conduits | 3 (2–3) | 3 (2–3) | 0.934 |
| Number of arterial conduits | 1 (1–2) | 1 (1–2) | 0.235 |
| Number of venous conduits | 1 (1–2) | 1 (1–2) | 0.375 |
| Complete revascularisation | 55.9 (307/549) | 53.0 (274/517) | 0.356 |
| Medication at discharge | |||
| Any antiplatelet therapy | |||
| Aspirin | 91.3 (501/549) | 91.1 (471/517) | 1.000 |
| Thienopyridine | 56.8 (312/549) | 61.5 (318/517) | 0.135 |
| Statin | 78.9 (433/549) | 81.2 (420/517) | 0.358 |
| Beta blocker | 80.7 (443/549) | 79.3 (410/517) | 0.592 |
| ACEI | 50.1 (275/549) | 53.8 (278/517) | 0.244 |
| ARB | 9.3 (51/549) | 8.7 (45/517) | 0.749 |
Data are presented as median (IQR) or percentage (n).
P values highlighted in bold suggest statistical significance (p<0.05).
ACEI, ACE inhibitors; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; LAD, left anterior descending artery; LMCAD, left main coronary artery disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery; 2VD, two-vessel disease; 3VD, three-vessel disease.